Introduction: The treatment of fibroblast cells with Azacitidine activate neural related genes and causes Alzheimer’s and Parkinson’s pathways activation. Azacytidine is a substance and inhibitor of DNMT enzymes. This causes activation of genes by demethylation. It has been shown many diseases are resulting from cellular epigenome distribution. It has been proposed that epigenetic changes in in-vitro made models of the relationship between epigenetic changes and disease and a proof for their relation in initiation of diseases. In this study, we showed that methylation dysregulation of fibroblast cells could be a determining factor for Neuro-Diseases.
Methods: The data of six samples consisted of three control samples and three samples of cells treated by AZA extract from NCBI site and its heat map were determined. Then the expressed different sections were extracted and eventually the network was plotted by string.
Results: It was shown that pathways related to brain and nervous diseases like Alzheimer’s and Parkinson’s have increased in AZA treated cells. These results indicate that demethylation of the genome can be one of the causes of neurological diseases. This result has been support by the fact that autoimmune diseases initiated after deregulation of methylation.
Conclusion: It can be concluded that methylation deregulation could initiate Alzheimer and Parkinson diseases. So use of AZA and other epigenetic regulators must be check and precautions have to be held. This result also could be significant because many of other nutrition we take has many epigenetic regulators such as grapes which have methylation inhibitors.